[Alternative schemes of eradication therapy and ways of overcoming acquired resistance of Helicobacter pylori to the treatment].
The author believes that eradication of Helicobacter pylori (HP) should be strictly justified and confined to cases with confirmed diagnosis of HP. Ineffective HP eradication leads to acquired resistance of HP to anti-chelicobacter therapy. How to overcome this resistance is shown.
Tsimmerman
Ia S
IaS
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial / Q000502:physiology; D004359:Drug Therapy, Combination / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000523:psychology; D016480:Helicobacter pylori / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010349:Patient Compliance; D019936:Probiotics / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D004791:Enzyme Inhibitors